Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 5Neoplasms 3Carcinoma, Renal Cell 2Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Lung Neoplasms 1Locally Advanced Rectal Adenocarcinoma 1Liposarcoma 1Leiomyosarcoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 25Gemcitabine 16Trabectedin 12Ifosfamide 12Radiotherapy 11Docetaxel 10Dacarbazine 8pazopanib 7Nivolumab 6Specimen Handling 5Biopsy 5liposomal doxorubicin 4Temozolomide 4pembrolizumab 3Sunitinib 3Sorafenib 3Radiation 3Magnetic Resonance Spectroscopy 3Filgrastim 3rucaparib 2pegfilgrastim 2olaratumab 2eribulin 2durvalumab 2cixutumumab 2cemiplimab 2brostallicin 2belinostat 2avelumab 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leiomyosarcoma × sotigalimab × Clear all
NCT03719430 2025-04-29

APX005M and Doxorubicin in Advanced Sarcoma

Columbia University

Phase 2 Active not recruiting
27 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡